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Abstract: In recent years, next-generation sequencing (NGS) was employed to decipher the structure
and composition of the microbiota of the airways in cystic fibrosis (CF) patients. However, little is
still known about the overall gene functions harbored by the resident microbial populations and
which specific genes are associated with various stages of CF lung disease. In the present study,
we aimed to identify the microbial gene repertoire of CF microbiota in twelve patients with
severe and normal/mild lung disease by performing sputum shotgun metagenome sequencing.
The abundance of metabolic pathways encoded by microbes inhabiting CF airways was reconstructed
from the metagenome. We identified a set of metabolic pathways differently distributed in
patients with different pulmonary function; namely, pathways related to bacterial chemotaxis and
flagellar assembly, as well as genes encoding efflux-mediated antibiotic resistance mechanisms
and virulence-related genes. The results indicated that the microbiome of CF patients with low
pulmonary function is enriched in virulence-related genes and in genes encoding efflux-mediated
antibiotic resistance mechanisms. Overall, the microbiome of severely affected adults with CF seems
to encode different mechanisms for the facilitation of microbial colonization and persistence in
the lung, consistent with the characteristics of multidrug-resistant microbial communities that are
commonly observed in patients with severe lung disease.
Keywords: cystic fibrosis; lung disease; lung microbiome; shotgun metagenomics; bioinformatics;
metabolic pathways; virulence genes
1. Introduction
Subjects affected by cystic fibrosis (CF) experience a progressive loss of pulmonary functions
accompanied by an increased burden of chronic infections. The respiratory microbial composition is
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particularly relevant for patients with CF. In fact, bacterial lung infections reduce life expectancy in
patients with CF (the median predicted survival age is equal to 41.6, as reported in the Cystic Fibrosis
Foundation Patient Registry [1]), and represent the primary cause of morbidity and mortality in CF
patients [2]. In the last decade, the emergence of high-throughput sequencing approaches, coupled
with the development of new bioinformatics pipelines designed to cope with metagenomics data,
has revolutionized the study of complex bacterial communities such as the airway microbiota of
CF patients, thereby improving our understanding of this largely unknown “microbial black-box”.
This understanding of how a bacterial community changes over time and over the course of CF disease
progression has revealed a different bacterial community structure upon pulmonary exacerbations
(such as a reduced bacterial diversity and an increasingly conserved community composition) coupled
with a decline in pulmonary health, antibiotic treatment, and patient age [3–11]. No overall changes
in total bacterial density with exacerbation was observed [12], suggesting that shifts in the relative
abundance of bacterial community members, rather than changes in total bacterial density, are more
likely to be associated with alterations in clinical state [12].
In previous studies [13,14], we provided new insights into the features of the bacterial communities
of patients with CF, improving our current knowledge about the airway microbiota composition
and polymicrobial interactions in patients following a severe decline in lung function and with
different lung disease statuses (normal/mild vs. moderate vs. severe). Although the description
of taxonomic groups colonizing the airways of CF patients has helped in the understanding of how
bacterial species change during disease progression, the overall gene content harbored by these
communities remains largely unknown. Since metabolic and functional features of a microbial species
are the dominant factors determining its ability to survive in a given environment (e.g., CF patients’
lungs) [15], untargeted metagenomic approaches may provide deep insights into the microbial CF lung
metagenome, permitting the identification of gene sets involved in functional pathways associated
with a worsening clinical condition [16].
In the present study, we performed a deep metagenomic investigation to probe the lung
microbiome of twelve CF patients with mild (Forced expiratory volume in one second (FEV1) > 70%)
and severe (FEV1 < 40%) lung disease. We aimed to investigate whether patients with different disease
severities may indeed have a different representation of “keystone genes” in their lung microbiota.
To the best of our knowledge, only a few works have already inspected the CF microbiome through
shotgun metagenomes, and most of them are case reports on a limited number of patients [17,18]
or on specific metabolic functions [19]. Moving away from taxonomic inventories towards a better
understanding of CF microbiome genes opens a new avenue for the identification of the microbial
gene repertoire associated with CF lung disease.
2. Results
2.1. Clinical Characteristics of Enrolled Patients and Culture-Based Diagnostic Microbiology
The clinical status of the individual subjects is reported in Table 1. The study cohort includes
twelve patients (aged 18–46 years; median = 28) with CF who were in stable clinical conditions, without
any pulmonary exacerbation and not undergoing antibiotic therapy (i.v. or oral) in the previous four
weeks before specimen collection. The normal/mild (FEV1 > 70% predicted) and severe (FEV1 < 40%
predicted) groups also differed in the extent of repeated antibiotic exposure and in their mean age
being equal to (mean ± standard error) 25.33 ± 2.216 and 33.83 ± 3.146 years in the normal/mild
and the severe group, respectively (two-tailed t-test; p value = 0.0313). In addition, the severe group
tended to receive more uniform antimicrobial agents by the inhalation of aerosolised antibiotics
during maintenance therapy, such as aerolized colistimethate and azithromycin, with respect to the
normal/mild group (Table 1). Traditional culture-based diagnostic microbiology revealed the presence
of Pseudomonas aeruginosa and Staphylococcus aureus, being the dominant bacterial species in patients
with severe and mild respiratory function, respectively (Table S1). Other minor taxa were Achromobacter
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xylosoxidans, Rothia mucilaginosa, Veillonella parvula, Stenotrophomonas maltophilia, Gemella sanguinis and
Escherichia coli.
Table 1. Demographic and clinical characteristics of patients with normal/mild (Forced expiratory
volume in one second (FEV1) > 70%) and severe (FEV1 < 40%) lung disease status enrolled in the study.
Study
ID Age Gender CFTR Genotype BMI
Average
Annual
FEV1%
Value
Lung
Disease
Status
Number of
Exacerbations
in the Last
5 Years
Maintenance
Antimicrobial
Therapy 1
BS29 25 F F508del/L1077P 23.1 72 normal/mild 20 (2–7) AT
BS47 33 M F508del/N1303K 23.8 94 normal/mild 5 (1–2) AA, AC
MS1 30 F G1244 E/G1244 E 22.9 83 normal/mild 5 (0–4) AC
GNR19 18 M F508del/F508del 21.4 80 normal/mild 9 (1–3) None
GNR5 24 M F508del/12491G>A 22.7 72 normal/mild 9 (0–3) None
BNR22 22 F F508del/G85E 22.1 81 normal/mild 23 (2–7) AT, AZ
BS19 36 M F508del/W1282X 24.9 37 severe 18 (3–4) AC, AZ
BS51 36 M F508del/2789+5G>A 21 38 severe 16 (2–6) AC, AZ
BS85 34 M F508del/1259insA 18.8 21 severe 15 (2–5) AC, AZ
BNR15 46 F F508del/F508del 19.7 37 severe 16 (2–4) AC, AZ
BNR20 25 M F508del/F508del 23.3 36 severe 36 (4–11) AA, AC
BNR49 26 M N1303K/G85E 19.9 29 severe 10 (1–3) AC
1 AT, aerosolized tobramycin; AA, aerosolized aztreonam; AC, aerosolized colistimethate; AA, aerosolized
aztreonam; AZ, azithromycin.
2.2. Metabolic Community Structure between Patient Groups
Sequencing yielded > 15 M paired-end sequences for each sample, with 1–5% of them being
of putative microbial origin (the remaining being human DNA). This confirmed that human
contamination still represents a considerable drawback in the metagenomic analysis of human sputum
samples, as already reported in other metagenomics studies [20,21]. From 12 samples, a total of 5.4 M
microbial sequences (mean ± standard error per sample, 453,824 ± 41,349) were included in the
analysis (Table S2). The HMP Unified Metabolic Analysis Network (HUMAnN) analysis revealed
47 pathways which were differently distributed across all samples (Figure S1). The principal component
analysis (PCA) analysis on metabolic and regulatory data (Figure 1) explained almost 80% of the total
variance reporting a distinct sample distribution for normal/mild and severe patient groups.
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In particular, the separation of normal/mild samples from severe samples was largely driven
by 6 pathways: biotin metabolism (Ko:00780), geraniol degradation (Ko:00281), bacterial chemotaxis
(Ko:02030), valine leucine and isoleucine degradation (Ko:00280), the bacterial secretion system
(Ko:03070), and flagellar assembly (Ko:02040). The Kruskal–Wallis one-way analysis of variance
confirmed this result with five out of six previously identified pathways displaying higher values in
the severe group patients compared to the normal/mild ones (Figure 2). Overall, 31 pathways were
equally distributed between the two groups considered (Figures S2 and S3), whereas 16 pathways
were differentially distributed in the two groups, being found mainly in patients with normal/mild
(5 pathways) and severe disease (11 pathways), respectively (Figure 2).
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2.3. Metagenomic Functional Differences Suggest Distinct Ecological Roles within the Cystic
Fibrosis Microbiome
In order to establish a set of gene putatively available in CF lung communities, metagenomic
reads were assembled into contigs. We were able to assemble an average of 1655 contigs (s.e. 526) per
sample (N50 values ranging from 645 to 1655) (Figure S4 and Table S2). The gene-calling step predicted
a mean of 5014 open reading frames (ORFs) with a standard error of 1266. The functional potential
harbored by microbiomes was inferred, predicting gene functions by homology using the evolutionary
genealogy of genes: non-supervised orthologous groups (eggNOG) database (Figure 3).
Both patient gro ps showed a assive presence of tra s rter proteins, with the severe group
reporting i er values than the normal/mild group. The Transporter Cl ssification Database
(TCDB) analysis highlighted the possibl presence of antibiotic resistance proteins indicating an
imbalanced distribution of the multidrug resistance efflux pumps of the ATP-binding cassette (ABC)
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and resistance–nodulation–cell division (RND) super-families between the two groups of patients.
In particular, patients with severe disease showed a high presence of both ABC and RND super-families
members (Figure S5), thus suggesting the presence of efflux-mediated antibiotic resistance mechanisms.
Virulence protein counts were normalized using the total number of ORFs predicted in each sample.
Virulence (and virulence-related) factors displaying a significant difference between groups (two-tailed
Student’s t-test p-value ≤ 0.05, alpha = 0.05) are shown in Figure 4 (individual values for each patient
are reported in Figures S6 and S7).
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A larger presence of virulence factors was found in patients with severe disease, with antibiotic
resistance as the third most abundant category. The Resfams analysis [22] suggests that the microbes
in CF airways encode a diverse set of antibiotic resistance mechanisms; among them, the multidrug
resistance efflux pumps are the most represented (Figure 5). Overall, 17 out of 18 antibiotic resistance
categories showed higher values in patients with severe disease, with 8 of them reporting significant
differences. As expected, efflux mediated systems were the most abundant categories, all reporting
higher values for severe patients than for normal/mild ones (Figure 5 and Figure S8). Our results are
supported by culture-based analysis, which reveals the presence of multi-drug resistant bacteria in the
severe group (Table S1).
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2.4. Relationship between Functional Potential and Taxonomic Microbial Composition
To further characterize the airway microbiome of CF patients, the correlation between the
taxonomic and functional structure of the microbial community was examined. The dissimilarity of
the taxonomic community was significantly correlated with the functional community dissimilarity
(Mantel test with Pearson correlation coefficient and 1000 permutations; p-values < 0.05), implying
a relation between the species distribution patterns and the functional distribution of the whole
airway community. Otherwise, the metabolic pathway distribution (Kyoto Encyclopedia of Genes and
Genomes (KEGG) analysis) was poorly correlated with other features, reporting significant correlations
only with antibiotic resistance gene distribution and taxonomic structure (Table S3).
To further identify the driving forces for the taxonomic distribution, the relative influence of
functional genes, metabolic pathway distribution, virulence factors, and antibiotic resistance genes
were rendered by using boosted tree models on principal components derived from each feature.
Principal components with an eigenvalue > 1 in total accounted for more than 85% of the total variance
and were therefore chosen for training boosted regression trees (Table S4). In boosted tree models,
measures of relative influence quantify the importance of a given predictor; the variables that have
a weak effect on prediction therefore have, by extension, scarcely an influence on the variable that
the model tries to predict [23]. Therefore, factors that have a minimal relative influence in predicting
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the abundance of a given taxon are poorly connected with the distribution of that taxon. Although
the use of orthogonal composite variables (as reported in the method section) reduced type I errors,
the contribution of each original variable cannot be inferred directly. To partially overcome this
limitation, the most dominant variables contributing to each component (top-50% eigenvalues of K, E,
A, and V) were reported in Table S4.
Based on the results reported in this study, the metabolic pathway distribution inferred with
KEGG (K) was the major factor able to predict the microbial taxonomic structure, whereas the gene
distribution obtained with eggNOG (E) had little influence on the whole community, affecting only the
distribution of a limited number of species (Figure 6).
Surprisingly, antibiotic resistance genes (A) were related to three bacterial species only:
Achromobacter xylosoxidans, Fusobacterium periodonticum, and an unclassified member of the Bordetella
genus. A. xylosoxidans strains, intrinsically resistant to many classes of antimicrobial agents, have been
associated with CF [24,25], as well as F. periodonticum, which has been reported to increase its presence
during exacerbation [26]. Conversely, virulence factors (V) (mainly comprising genes previously
identified in pathogenicity islands, virulence proteins, and antibiotic resistance genes Figures S7 and 4)
were not related to any particular species reporting the lowest values of relative influence.
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applications (MvirDB), V1) for taxono i icrobial lung community evaluated through
“booster regression trees” models. The r l fl ce of di ferent principal compo ent to each
bacterial speci s detec d was clustered with t e unweighted pair-group method with arithmetic mean
(UPGMA) method based on Pearson’s correlati n and a tree was reported on the right side of the plot.
Boxes report the main group of taxa detected through a cluster analysis.
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3. Discussion
In an endeavor to better understand the complexity of CF microbiomes in patients with high/low
pulmonary function, we performed a metagenomics investigation of the bacterial communities in the
airways of patients with CF focusing on the identification of a set of functional features associated
with different lung disease statuses in the present study.
Sputum specimens, which represent by far the most widely used sample to access the airway
microbiota of CF disease [27–30], were collected from twelve patients with CF. As recently indicated
by Dickson and colleagues [31], although use of sputum can introduce an additional risk of upper
airway contamination, the presence of oropharyngeal microbiota does not obscure the meaningful
microbial signal in sputum which is correlated with established indices of lung health. To date, in CF
metagenomics, published studies have focused on the sputum derived from CF patients [17,32–34].
The shotgun metagenomics approach, which provides the gene catalogue of the microbial community,
allows an insight into some functional features to be gained (e.g., the presence of metabolic pathways
and potential antibiotic resistance genes), in addition to accurate species-level taxonomic assignments.
In the first metagenomic study performed by Willner and colleagues [33], the airways of diseased
and non-diseased individuals showed a potentially different microbial community metabolism
(inferred from the recovered gene catalogue of the microbiome), suggesting that the community
metabolism is dynamic and variable among patients differing in their health status. In the present
work, the abundances of metabolic pathways encoded by microbes inhabiting CF airways of patients
with high/low pulmonary function were reconstructed from the metagenome. The metabolic pathway
distribution described in this work was in accordance with the one described in other studies [19,32],
with pathways related to amino acid catabolism, nucleotide metabolism, and stress responses reporting
high values in both normal/mild and severe patients. Several pathways were uniformly distributed
among patients, regardless of their clinical condition, reflecting a large set of core functions typical
of host-associated microbes. Indeed, according to the previous studies mentioned above [19,32],
there was little variation in the metagenome pathway distribution, with sixteen pathways only
reporting different abundance values between the two groups of patients inspected here. Interestingly,
we identified a set of metabolic pathways correlated with the worsening of patients’ clinical conditions;
in particular, two pathways, the bacterial chemotaxis pathway (Ko:02030) and the flagellar assembly
pathway (Ko:02040), were reported as clinically relevant according to previous works [35–39]. Indeed,
one pathway was associated with Pseudomonas aeruginosa lung infection (bacterial chemotaxis pathway),
whereas the second (flagellar assembly pathway) was classified as a potent mediator of virulence
in Gram-negative bacteria such as P. aeruginosa strains. Moreover, the motB gene (a component of
the flagellar assembly pathway) is known to aid bacterial chemotaxis and flagellar assembly; also,
its product (a membrane protein, flagellar motor protein) was recognized as a potential novel vaccine
target in Vibrio cholerae [40]. We can hypothesize that the difference in the representation of the
above-mentioned pathways (Ko:02030 and Ko:02040) could rely on both P. aeruginosa strain differences
(between the two disease groups) as well as on the presence of other bacteria in the CF microbiome
which carry the same gene sets. The presence of P. aeruginosa and other Gram-negative strains that
could be responsible for the appearance of these pathways were also revealed by cultivation methods
analysis, as reported in Figure S9. However, the limited number of patients analyzed in our study does
not allow for definitive, statistically-based conclusion on this issue.
In addition to microbial genes involved in metabolic metabolism, genes involved in antibiotic
resistance are also powerful indicators of the microbial community’s adaptation to the CF lung [17].
Indeed, the top-50% KEGG pathways (reported in Table S4) were mainly involved in the metabolism
of amino acids and nucleotides and may be linked to bacterial proliferation and adaptation in the
lungs. An increased presence of genes involved in both nucleotide and amino acid metabolism may,
in fact, indicate a huge presence of both types of molecules which, in turn, may come from neutrophil
extracellular traps, bacterial biofilms and the action of human and bacterial proteases [32,41–44].
Moreover, a large number of genes classified with eggNOG belonged to the transporter families. Their
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further analysis by using the Transporter Classification Database (TCDB) permitted us to identify a
massive presence of families connected with antibiotic resistance mechanisms, especially in patients
with severe lung disease. The presence of genes related to antibiotic resistance mechanisms was
confirmed by the Hidden Markov model (HMM) (Resfams), which accurately predicts new resistance
functions from sequence alone [22]. The efflux-mediated system, which represents the widespread
drug resistance mechanism common to many microorganisms, was the most represented gene function.
Interestingly, the presence of P. aeruginosa and Staphylococcus aureus was not related to the differential
abundance of antibiotic resistance genes and virulence factors. Indeed, virulence and resistance
genes have been found to be spread throughout the whole CF bacterial community and are poorly
related to the presence of single taxa, suggesting that the emergence of these mechanisms should
be attributed to a particular clinical condition (normal/mild or severe lung disease) of CF patients.
In fact, significant differences in the percentage of total Antibiotic Resistance (AR) functions encoded
in microbial genomes between normal/mild and severe groups were found. Overall, there was a
significant AR mechanism enrichment in patients with severe lung disease due to several years of
exposure to antimicrobial drugs. It is well known that several antimicrobial agents and complex
regimens are used for prophylaxis, eradication, treatment of exacerbations, and chronic suppressive
therapy [45,46], paving the way for the emergence and spreading of AR mechanisms throughout
the lung microbial community. In particular, oral, intravenous, and inhaled antibiotic courses are
often frequent and prolonged, especially with increasing age and declining pulmonary status [47] as
those characterizing the patients with severe lung disease. As underlined by Zhao and colleagues [28],
an antibiotic administered closer to the time of sampling would be expected to have a greater impact on
the microbial community than that same antibiotic would have when administered at a longer interval
from the sampling time. Even if, on the date of sampling and in the 30 days before sample collection,
antibiotic administration through an IV route was not given to our patients, we can hypothesize that
patients with severe lung disease, having an average higher age than those from the normal/mild
group, experienced several years of exposure to antimicrobial drugs, leading to periodic selection for an
AR microbiota and resulting in a higher frequency and diversity of AR genes in their lung microbiota.
The depth and diversity of AR genes uncovered by metagenomic studies in CF patients with different
disease statuses brings to light the need for new strategies to combat antibiotic-resistant pathogens [48].
As reported by King and colleagues [49], the metagenomic profiles of human microbiota are becoming
increasingly characterized, and growing data suggests that imbalances of the microbiota could lead to
a disease status [50].
4. Materials and Methods
4.1. Ethics Statement
The study was approved by the Ethics Committees of Children’s Hospital and Research Institute
Bambino Gesù (Rome, Italy), Cystic Fibrosis Center, Anna Meyer Children’s University Hospital
(Florence, Italy) and G. Gaslini Institute (University of Genoa, Genoa, Italy) (Prot. N. 681 CM of
2 November 2012; Prot. N. 85 of 27 February 2014; Prot. N. FCC 2012 Partner 4-IGG of 18 September
2012). Informed written consent was given by all adult subjects before enrollment in the study.
All sputum specimens were produced voluntarily. All procedures were performed in agreement
with the “Guidelines of the European Convention on Human Rights and Biomedicine for Research in
Children” and the Ethics Committee of the three CF Centers involved. All measures were obtained
and processed ensuring patient data protection and confidentiality.
4.2. Patients
Twelve patients with CF (aged 18–46 years), older than six years, were enrolled in the study
between September 2012 and April 2013. The cohort consisted of clinically stable patients without
any pulmonary exacerbation and who were not undergoing antibiotic therapy (i.v. or oral) in the
Int. J. Mol. Sci. 2017, 18, 1654 10 of 16
previous four weeks before specimen collection [51,52]. Patients were treated according to the current
standards of care [53] with at least four microbiological controls per year [54]. At each visit, clinical data
collection and microbiological status (colonizing pathogens with available cultivation protocols) were
performed according to the European CF Society standards of care [55]. Forced expiratory volume in
one second as a percentage of predicted (%FEV1) is a key outcome of the monitoring of lung function
in CF [56]. All enrolled patients had an absence of an acute pulmonary exacerbation. Patients were
classified into two groups, “normal/mild” (FEV1 > 70%) and “severe” (FEV1 < 40%), by estimating
their average annual FEV1 value on the basis of multiple spirometric measurements over the two years
before their enrollment. FEV1 values were measured according to the American Thoracic Society (ATS)
and the European Respiratory Society (ERS) standards [57,58]. The lower limit of age for subjects
with “normal/mild” disease was 15 years old, while that of subjects with severe disease was 25 years
old. The study was approved by the Ethics Committees of Children’s Hospital and Research Institute
Bambino Gesù (Rome, Italy), Cystic Fibrosis Center, Anna Meyer Children’s University Hospital
(Florence, Italy) and G. Gaslini Institute (University of Genoa, Genoa, Italy), as stated in the ethical
statement. The demographic and clinical characteristics of patients are reported in Table 1. The number
of exacerbations (as defined by a cluster of symptoms and signs as previously indicated [51,52]) was
determined in the five years before the enrollment.
4.3. Sample Processing
The microbiome analysis was performed on sputum samples. Upon expectoration, CF sputum
samples were immediately treated for 15 min with Sputolysin (Calbiochem, La Jolla, CA, USA) in
accordance with the manufacturer’s instructions and split into aliquots for culture and molecular
analyses. Aliquots for culturable analysis were immediately examined, and the remaining aliquots
were frozen and stored at −80 ◦C for subsequent DNA extraction and metagenomic analysis. Bacterial
detection and identification were performed as previously reported [13]. The microbiological status of
the individual subjects is reported in Table S2.
4.4. DNA Extraction Procedures and Sequencing
About 400 µl aliquots of frozen sputum were subjected to genomic DNA extraction using acetyl
trimethylammonium bromide (CTAB) protocol, according to the procedure previously reported [59].
Sample aliquots were spun at 10,000× g to pellet cellular material. After the removal of the supernatant,
cell pellets were re-suspended in 567 µL of autoclaved and 0.2 filtered TE pH 8 and incubated
for 1 h at 37 ◦C with 30 µL 10% sodium dodecyl sulfate (SDS) and 3 µL 20 mg/mL Proteinase K
(Sigma-Aldrich, St. Louis, MO, USA). Samples were then incubated for 10 min with 100 µL of 5 M
NaCl prepared with sterile water and 80 µL of CTAB/NaCl solution (4.1 g NaCl, 10 g CTAB in
100 mL sterile water). Following incubation, extracts were purified using phenol chloroform extraction,
and DNA was recovered by isopropanol precipitation. Pelleted DNA was washed twice with cold
70% ethanol, allowed to air dry, and re-suspended in 30 µL of sterile water. Quantity and integrity
of DNA extracted were assessed by Qubit 2.0 fluorometer (Invitrogen, Life technologies) and gel
electrophoresis, respectively. Library preparation and DNA sequencing were performed following
the standard pipelines for Illumina HiSeq 2000, PE100 sequencing (Beijing Genomics Institute, BGI,
Shenzhen, Guangdong, China), as described in Supplementary Information S1. Raw sequence data
reported in this study have been deposited in the National Center for Biotechnology Information
(NCBI) “Sequence Read Archive” (SRA) under the project accession PRJNA316056.
4.5. Bioinformatic Analyses
Sequence quality was ensured by trimming reads using StreamingTrim 1.0 [60], with a quality
cutoff of 20. Bowtie2 [61] was used to screen out human-derived sequences from metagenomic data
with the latest version of the human genome available in the NCBI database (GRCh38) as reference.
Sequences displaying a concordant alignment (a mate pair that aligns with the expected relative mate
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orientation and with the expected range of distances between mates) against the human genomes
were then removed from all subsequent analyses. Metabolic and regulatory patterns were estimated
using HUMAnN [62] and considered only those pathways with a coverage value ≥ 80%, whereas
the taxonomic microbial community composition was assessed using MetaPhlAn2 [63]. Reads were
assembled into contigs using the SPAdes microbial assembler [64] with automatic k-mer length
selection. To establish an airway microbiome gene catalog [65], we first removed contigs smaller than
500bp and then used MetaGeneMark [66] to predict open reading frames (ORFs). Translated protein
sequences obtained from assembled contigs were classified using Hmmer [67] with the eggNOG [68]
database trained on bacterial sequences (bactNOG). Each protein was classified according to its best hit
with an e-value lower than 0.001 as suggested in [69]. Proteins classified as transporters were further
inspected using Basic Local Alignment Search Tool (BLAST) against the Transporter Classification
Database (TCDB) [70] to obtain a more detailed classification. Similarly, the MvirDB [71] database was
used to inspect the distribution of virulence factors among our samples. We classified each sequence
based on its BLAST best hit with an e-value lower than 1 × 10−20 in order to minimize the number of
alignments that could be found by chance. Proteins that did not match any reference sequence were
excluded from the analysis. Finally, predicted proteins were screened for antibiotic resistance activity
based on the workflow described in [22] and validated for the Resfams database.
4.6. Statistical Analyses
All statistical analyses were implemented in R (R Core Team (2015), version 3.2.3, R Foundation
for Statistical Computing, Vienna, Austria) with the help of various packages. The distribution of
metabolic pathways was assessed using the principal component analysis (PCA) on normalized data
using the “rda” function of the vegan package version 2.3.2 [72]. The 20 metabolic pathways that
varied greatly between normal/mild and severe groups were selected through the similarity of the
percentages analysis (“simper” function) and used for PCA analysis (vegan 2.3.2). The Kruskal–Wallis
one-way analysis of variance was used to test whether the metabolic and regulatory pathways of
different patient groups originated from distinct distributions using the “Kruskal” function of the
agricolae package (version 1.2.3). The distribution of ortholog genes, virulence factors, and antibiotic
resistance mechanisms was normalized by the total number of open reading frames (ORFs) detected
for each sample, and the differences between normal/mild and severe groups were assessed using
the two-tailed Student’s t-test for each category (“t.test” function). The correlation between two
dissimilarity matrices, obtained from metagenomics data such as the metabolic pathway or gene
distribution, was assessed by using the Mantel test (vegan 2.3.2) as reported in other studies [73,74].
Basically, each table was transformed into a dissimilarity matrix using the “Bray–Curtis” dissimilarity
index. By doing so, all dissimilarity matrices were reduced to the same rank, making it possible
to use the Mantel test to inspect the correlation between them. The influence of gene patterns,
metabolic modules distribution, virulence factors, and antibiotic-resistance genes on the taxonomic
microbial composition was evaluated using “boosted regression tree” models [23] with 5000 trees,
10-fold cross-validation, and three-way interactions (gbm package version 2.1.1). Testing multiple
individual variables assumed to be correlated with each other may inflate type I errors due to the high
number of comparisons made [75]. To reduce the number of comparisons, and therefore to minimize
the number of false positive correlations [75], orthogonal composite variables were derived from
principal component analysis (PCA) for each factor explored, retaining only those components with an
eigenvalue > 1. The derived variables were used for training boosted regression trees, minimizing the
number of comparisons and, thus, reducing potential type I errors. A hierarchical cluster analysis was
performed based on the average linkage method with “Pearson’s distance” metrics (“hclust” function).
All graphical representations of data were performed using the ggplot2 package version 2.0.0 [76].
To minimize the type I errors in multiple comparisons, p-values where adjusted using a false discovery
rate (FDR).
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5. Conclusions
Our results highlight that different pulmonary conditions in patients with CF co-occur with a
different microbiome gene repertoire. In particular, an imbalanced distribution of virulence factors
along with AR genes and metabolic pathways has been found. Understanding the role of the CF airway
microbiome and detecting microbiome genes associated with lower lung function are key challenges for
the delivery of new potential biomarkers for the management of bacterial infection in CF patients and
the improvement of health care treatment. Our study was limited to twelve subjects; therefore, a larger
scale study is needed to more completely characterize the spectrum of microbiome changes associated
with the decreasing of pulmonary function. Longitudinal metagenomic analysis, which we plan to
evaluate in ongoing studies, may help in understanding imbalances down to the single gene level,
possibly helping to find new therapeutic strategies for targeting personalized disease phenotypes.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1654/s1.
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